Developmental Therapeutics Recent Publications

• Nanotechnology approaches to drug delivery for the treatment of ischemic stroke.Peng B, Mohammed FS, Tang X, Liu J, Sheth KN, Zhou J. Bioact Mater. 2025 Jan; 2024 Sep 23. PMID: 39386225.
• Efficient standardization of clinical T(2)-weighted images: Phase-conjugacy e-CAMP with projected gradient descent.Zhang HZ, Elsaid NMH, Sun H, Tagare HD, Galiana G. Magn Reson Med. 2024 Dec; 2024 Jul 10. PMID: 38988054.
• Branching in poly(amine-co-ester) polyplexes impacts mRNA transfection.Shin K, Suh HW, Suberi A, Whang CH, Ene M, Grundler J, Grun MK, Saltzman WM. Biomaterials. 2024 Dec; 2024 Jun 27. PMID: 38986360.
• Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, Khan H, Azzoli C, Hofstetter M, Sadanaga T, Herbst R, Politi K, Lee CG, Elias JA. Transl Oncol. 2024 Nov; 2024 Aug 22. PMID: 39178575.
• High-quality lipid suppression and B0 shimming for human brain (1)H MRSI.Kumaragamage C, McIntyre S, Nixon TW, De Feyter HM, de Graaf RA. Neuroimage. 2024 Oct 15; 2024 Sep 12. PMID: 39276817.
• Enantioselective S-Alkylation of Sulfenamides by Phase-Transfer Catalysis.Champlin AT, Kwon NY, Ellman JA. Angew Chem Int Ed Engl. 2024 Oct 14; 2024 Sep 12. PMID: 39058627.
• Synthesis of Monodehydro-Diketopiperazines Enabled by Cp*Rh(III)-Catalyzed Amine-Directed N-H Functionalization.Molas JC, Poag EM, Ellman JA. Org Lett. 2024 Oct 11; 2024 Sep 27. PMID: 39332014.
• Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. J Clin Oncol. 2024 Oct 10; 2024 Jul 31. PMID: 39083724.
• CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. Nature. 2024 Oct 9; 2024 Oct 9. PMID: 39385035.
• Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG. Lancet Haematol. 2024 Oct 8; 2024 Oct 8. PMID: 39393368.
• Bacterial small molecule metabolites implicated in gastrointestinal cancer development.Turocy T, Crawford JM. Nat Rev Microbiol. 2024 Oct 7; 2024 Oct 7. PMID: 39375475.
• Targeted therapies for myelodysplastic Syndromes/Neoplasms (MDS): current landscape and future directions.Bidikian A, Bewersdorf JP, Shallis RM, Getz TM, Stempel JM, Kewan T, Stahl M, Zeidan AM. Expert Rev Anticancer Ther. 2024 Oct 5; 2024 Oct 5. PMID: 39367718.
• Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A. Oncologist. 2024 Oct 3. PMID: 39022993.
• Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.Jayakrishnan R, Kwiatkowski DJ, Rose MG, Nassar AH. Oncologist. 2024 Oct 3. PMID: 38907669.
• Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, Yefet LS, Tonn JC, Gui C, Ostrom QT, Barnholtz-Sloan J, Perry A, Ellenbogen Y, Hanemann CO, Jungwirth G, Jenkinson MD, Tabatabai G, Mathiesen TI, McDermott MW, Tatagiba M, la Fougère C, Maas SLN, Galldiks N, Albert NL, Brastianos PK, Ehret F, Minniti G, Lamszus K, Ricklefs FL, Schittenhelm J, Drummond KJ, Dunn IF, Pathmanaban ON, Cohen-Gadol AA, Sulman EP, Tabouret E, Le Rhun E, Mawrin C, Moliterno J, Weller M, Bi WL, Gao A, Yip S, Niyazi M, Aldape K, Wen PY, Short S, Preusser M, Nassiri F, Zadeh G. Neuro Oncol. 2024 Oct 3. PMID: 38695575.
• NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion.Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS. Mol Cancer Res. 2024 Oct 2. PMID: 38949523.
• CYP2E1 in 1,4-dioxane metabolism and liver toxicity: insights from CYP2E1 knockout mice study.Wang Y, Charkoftaki G, Orlicky DJ, Davidson E, Aalizadeh R, Sun N, Ginsberg G, Thompson DC, Vasiliou V, Chen Y. Arch Toxicol. 2024 Oct; 2024 Aug 27. PMID: 39192018.
• Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis.Muradashvili T, Yu M, Browning SL, Bar N, Gorshein E, Parker TL, Neparidze N. Leukemia. 2024 Oct; 2024 Aug 20. PMID: 39164408.
• Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma.Tripathi A, Tangen CM, Plets M, Li X, Tretiakova M, Humphrey PA, Adeniran A, Barata PC, Gulati S, Bergerot CD, Pruthi DK, Thompson IM, Lara PN Jr, Lerner SP, Pal SK, Shuch BM. BJU Int. 2024 Oct; 2024 Jul 16. PMID: 39014969.
• Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.McNamara B, Greenman M, Bellone S, Santin LA, Demirkiran C, Mutlu L, Hartwich TMP, Yang-Hartwich Y, Ratner E, Schwartz PE, Santin AD. Gynecol Oncol. 2024 Oct; 2024 Jul 8. PMID: 38981151.
• Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy.Diaz GM, Webb LT, Rabil MJ, Lokeshwar SD, Choksi AU, Leapman MS, Sprenkle PC. Curr Urol Rep. 2024 Oct; 2024 Jun 19. PMID: 38896314.
• Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning.Gross M, Haider SP, Ze'evi T, Huber S, Arora S, Kucukkaya AS, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Oct; 2024 Mar 27. PMID: 38536464.
• Unmet needs in cervical cancer - can biological therapies plug the gap?Greenman M, Chang YE, McNamara B, Mutlu L, Santin AD. Expert Opin Biol Ther. 2024 Sep 25; 2024 Sep 25. PMID: 39311611.
• Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Blood Adv. 2024 Sep 24. PMID: 38941537.
• Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway H, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Zhuoer X, Xu ML, Hasserjian RP, Loghavi S. Mod Pathol. 2024 Sep 23; 2024 Sep 23. PMID: 39322118.
• IL-1β Induces Human Endothelial Surface Expression of IL-15 by Relieving let-7c-3p Suppression of Protein Translation.Mullan CW, Summer L, Lopez-Giraldez F, Tobiasova Z, Manes TD, Yasothan S, Song G, Jane-Wit D, Saltzman WM, Pober JS. J Immunol. 2024 Sep 20; 2024 Sep 20. PMID: 39302113.
• Disulfide Tethering to Map Small Molecule Binding Sites Transcriptome-wide.Moon MH, Vock IW, Streit AD, Connor LJ, Senkina J, Ellman JA, Simon MD. ACS Chem Biol. 2024 Sep 20; 2024 Aug 28. PMID: 39192734.
• Prodrug nanotherapy demonstrates in vivo anticryptosporidial efficacy in a mouse model of chronic Cryptosporidium infection.Ranjan AP, Czyzyk DJ, Martinez-Traverso G, Sadiqova A, Valhondo M, Schaefer DA, Spasov KA, Jorgensen WL, Vishwanatha JK, Riggs MW, Castellanos-Gonzalez A, Anderson KS. RSC Pharm. 2024 Sep 19; 2024 Sep 19. PMID: 39372445.
• Microbial transformation of dietary xenobiotics shapes gut microbiome composition.Culp EJ, Nelson NT, Verdegaal AA, Goodman AL. Cell. 2024 Sep 19; 2024 Sep 19. PMID: 39321800.
• A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M. Clin Cancer Res. 2024 Sep 17; 2024 Sep 17. PMID: 39287821.
• Development of Ligands and Degraders Targeting MAGE-A3.Li K, Krone MW, Butrin A, Bond MJ, Linhares BM, Crews CM. J Am Chem Soc. 2024 Sep 11; 2024 Aug 27. PMID: 39190582.
• Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. J Thorac Oncol. 2024 Sep 10; 2024 Sep 10. PMID: 39260522.
• Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.Barata P, Tangen C, Plets M, Thompson IM Jr, Narayan V, George DJ, Heng DYC, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara PN Jr, Lerner SP, Balzer-Haas N, Pal SK. J Clin Oncol. 2024 Sep 10; 2024 Sep 10. PMID: 39255440.
• Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Clin Lymphoma Myeloma Leuk. 2024 Sep 8; 2024 Sep 8. PMID: 39368885.
• Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.Gupta V, Sehrawat TS, Pinzani M, Strazzabosco M. Gastroenterology. 2024 Sep 7; 2024 Sep 7. PMID: 39251168.
• Dynamic and structural insights into allosteric regulation on MKP5 a dual-specificity phosphatase.Skeens E, Maschietto F, Manjula R, Shillingford S, Lolis EJ, Batista VS, Bennett AM, Lisi GP. bioRxiv. 2024 Sep 5; 2024 Sep 5. PMID: 39282375.
• Pancreatic Cysts.Gonda TA, Cahen DL, Farrell JJ. N Engl J Med. 2024 Sep 5. PMID: 39231345.
• Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights.Muradashvili T, Liu Y, VanOudenhove J, Gu SX, Krause DS, Montanari F, Carlino MJ, Mancuso R, Stempel JM, Halene S, Zeidan AM, Podoltsev NA, Neparidze N. Leuk Lymphoma. 2024 Sep 3; 2024 Sep 3. PMID: 39225418.
• Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.Choi Y, Dharia NV, Jun T, Chang J, Royer-Joo S, Yau KK, Assaf ZJ, Aimi J, Sivakumar S, Montesion M, Sacher A, LoRusso P, Desai J, Schutzman JL, Shi Z. Clin Cancer Res. 2024 Sep 3. PMID: 38995268.
• Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review.Nasioudis D, Pashankar FD. Int J Gynecol Cancer. 2024 Sep 2; 2024 Sep 2. PMID: 38991656.
• Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer.Hartwich TMP, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi SP, Alexandrov LB, Yang-Hartwich Y, Coma S, Pachter J, Santin AD. Cancer Med. 2024 Sep. PMID: 39240189.
• Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Nat Med. 2024 Sep. PMID: 39164519.
• Akt is a mediator of artery specification during zebrafish development.Zhou W, Ghersi JJ, Ristori E, Semanchik N, Prendergast A, Zhang R, Carneiro P, Baldissera G, Sessa WC, Nicoli S. Development. 2024 Sep 1; 2024 Sep 2. PMID: 39101673.
• Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.Della Porta MG, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Lancet Haematol. 2024 Sep; 2024 Jul 19. PMID: 39038479.
• Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr. J Clin Oncol. 2024 Sep 1; 2024 Jul 22. PMID: 39038265.
• Enterococcus faecalis-derived adenine enhances enterohaemorrhagic Escherichia coli Type 3 Secretion System-dependent virulence.Martins FH, Rosay T, Rajan A, Carter HE, Turocy T, Mejia A, Crawford JM, Maresso AW, Sperandio V. Nat Microbiol. 2024 Sep; 2024 Jul 4. PMID: 38965331.
• Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.Liu M, Vathiotis I, Robbins CJ, Chan NNN, Moutafi M, Burela S, Xirou V, Schalper KA, Herbst RS, Syrigos K, Rimm DL. Mod Pathol. 2024 Sep; 2024 Jul 2. PMID: 38964502.
• Patterns of brain metastases response to immunotherapy with pembrolizumab.Mahajan A, Goldberg SL, Weiss SA, Tran T, Singh K, Joshi K, Aboian MS, Kluger HM, Chiang VL. J Neurooncol. 2024 Sep; 2024 Jul 4. PMID: 38963658.
• Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation.Su DG, Rehman S, Wang K, Deng Y, Rose MG, Dosani T, Kunstman JW. J Surg Res. 2024 Sep; 2024 Jun 20. PMID: 38905768.
• ZFYVE21 promotes endothelial nitric oxide signaling and vascular barrier function in the kidney during aging.Jiang Q, Song G, He L, Li X, Jiang B, Wang Q, Wang S, Kim C, Barkestani MN, Lopez R, Fan M, Wanniarachchi K, Quaranta M, Tian X, Mani A, Gonzalez A, Goodwin JE, Sessa WC, Ishibe S, Jane-Wit D. Kidney Int. 2024 Sep; 2024 May 24. PMID: 38797325.
• Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, Faller BA, Kortmansky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB. J Natl Cancer Inst. 2024 Sep 1. PMID: 38775718.
• Modifying the Backbone Chemistry of PEG-Based Bottlebrush Block Copolymers for the Formation of Long-Circulating Nanoparticles.Grundler J, Whang CH, Shin K, Savan NA, Zhong M, Saltzman WM. Adv Healthc Mater. 2024 Sep; 2024 May 22. PMID: 38734871.
• Challenges in management of older patients with chronic myeloid leukemia.Stempel JM, Shallis RM, Wong R, Podoltsev NA. Leuk Lymphoma. 2024 Sep; 2024 Apr 23. PMID: 38652861.
• Practical utilization of nonlinear spatial encoding: Fast field mapping and FRONSAC-wave.Zhang HZ, Constable RT, Galiana G. Magn Reson Med. 2024 Sep; 2024 Apr 23. PMID: 38651264.
• Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.Bertolini A, Nguyen M, Zehra SA, Taleb SA, Bauer-Pisani T, Palm N, Strazzabosco M, Fiorotto R. J Hepatol. 2024 Sep; 2024 Mar 28. PMID: 38554847.
• Variations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group.Tabor JK, Dincer A, O'Brien J, Lei H, Vetsa S, Vasandani S, Jalal MI, Yalcin K, Morales-Valero SF, Marianayagam N, Alanya H, Elsamadicy AA, Millares Chavez MA, Aguilera SM, Mishra-Gorur K, McGuone D, Fulbright RK, Jin L, Erson-Omay EZ, Günel M, Moliterno J. J Neurosurg. 2024 Sep 1; 2024 Mar 22. PMID: 38518289.
• Beyond HMAs: Novel Targets and Therapeutic Approaches.Getz TM, Bewersdorf JP, Kewan T, Stempel JM, Bidikian A, Shallis RM, Stahl M, Zeidan AM. Semin Hematol. 2024 Aug 30; 2024 Aug 30. PMID: 39389839.
• Cathepsin B Nuclear Flux in a DNA-Guided "Antinuclear Missile" Cancer Therapy.Cao F, Tang C, Chen X, Tu Z, Jin Y, Turk OM, Nishimura RN, Ebens A, Dubljevic V, Campbell JA, Zhou J, Hansen JE. ACS Cent Sci. 2024 Aug 28; 2024 Jul 15. PMID: 39220699.
• Clinical Presentation, Management, and Outcome in Neurolymphomatosis: A Systematic Review.Kaulen LD, Hielscher T, Doubrovinskaia S, Hoffmann DC, Kessler T, Traub BL, Baehring JM, Wick W. Neurology. 2024 Aug 27; 2024 Aug 5. PMID: 39102613.
• Prognostic implications of margin status in association with systemic treatment in a cohort study of patients with resection of colorectal liver metastases.Moaven O, Mainali BB, Valenzuela CD, Russell G, Cheung T, Corvera CU, Wisneski AD, Cha CH, Stauffer JA, Shen P. J Surg Oncol. 2024 Aug 25; 2024 Aug 25. PMID: 39183490.
• Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.Wu H, Sukhanova M, Tang H, Lu X, Zhong M, Deshpande H, Pollack SM, Laskin WB, Alexiev BA. Arch Pathol Lab Med. 2024 Aug 21; 2024 Aug 21. PMID: 39164013.
• Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study.Neparidze N, Godara A, Lin D, Le HH, Fixler K, Shea L, Everson S, Brittle C, Brunisholz KD. Healthcare (Basel). 2024 Aug 20; 2024 Aug 20. PMID: 39201218.
• Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A, Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG. J Clin Oncol. 2024 Aug 20; 2024 May 9. PMID: 38723212.
• Catalytic Enantioselective Sulfoxidation of Functionalized Thioethers Mediated by Aspartic Acid-Containing Peptides.Huth SE, Tampellini N, Guerrero MD, Miller SJ. Org Lett. 2024 Aug 16; 2024 Aug 5. PMID: 39102356.
• Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies.Raina K, Forbes CD, Stronk R, Rappi JP Jr, Eastman KJ, Zaware N, Yu X, Li H, Bhardwaj A, Gerritz SW, Forgione M, Hundt A, King MP, Posner ZM, Correia AD, McGovern A, Puleo DE, Chenard R, Mousseau JJ, Vergara JI, Garvin E, Macaluso J, Martin M, Bassoli K, Jones K, Garcia M, Howard K, Yaggi M, Smith LM, Chen JM, Mayfield AB, De Leon CA, Hines J, Kayser-Bricker KJ, Crews CM. Cell Chem Biol. 2024 Aug 15; 2024 Aug 7. PMID: 39116881.
• Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma.Aung TN, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, Kluger HM, Gerstein M, Rimm DL. Clin Cancer Res. 2024 Aug 15. PMID: 38837895.
• Monte Carlo simulations for free energies of hydration: Past to present.Jorgensen WL. J Chem Phys. 2024 Aug 14. PMID: 39136662.
• Parkinsonism Following Chimeric Antigen Receptor T Cell Therapy.Gudera JA, Baehring JM, Karschnia P. JAMA Neurol. 2024 Aug 12; 2024 Aug 12. PMID: 39133506.
• Addressing platelet insecurity - A national call to action.Gehrie EA, Young PP, Basavaraju SV, Bracey AW, Cap AP, Culler L, Dunbar NM, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey CA, Kaufman RM, Snyder EL. Transfusion. 2024 Aug 12; 2024 Aug 12. PMID: 39133194.
• Progression of Femoral Osteolytic Metastases after Intramedullary Nailing and Subsequent Salvage Techniques.Jiang W, Latich I, Lindskog D, Friedlaender G, Lee FY. Cancers (Basel). 2024 Aug 10; 2024 Aug 10. PMID: 39199585.
• Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities.Neparidze N, Godara A, Lin D, Le HH, Fixler K, Shea L, Everson S, Brittle C, Brunisholz KD. Healthcare (Basel). 2024 Aug 9; 2024 Aug 9. PMID: 39201146.
• Human AKR1C3 binds agonists of GPR84 and participates in an expanded polyamine pathway.Dudkina N, Park HB, Song D, Jain A, Khan SA, Flavell RA, Johnson CH, Palm NW, Crawford JM. Cell Chem Biol. 2024 Aug 9; 2024 Aug 9. PMID: 39163853.
• Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol-Coated Biodegradable Nanoparticles.Chang J, Shin K, Lewis JM, Suh HW, Lee J, Damsky W, Xu S, Bosenberg M, Saltzman WM, Girardi M. J Invest Dermatol. 2024 Aug 8; 2024 Aug 8. PMID: 39122142.
• Factors influencing timely diagnosis in neurolymphomatosis.Doubrovinskaia S, Egert A, Karschnia P, Scheffler GT, Traub BL, Galluzzo D, Huttner A, Fulbright RK, Baehring JM, Kaulen LD. J Neurooncol. 2024 Aug 8; 2024 Aug 8. PMID: 39115616.
• TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3.Perales O, Jilaveanu L, Adeniran A, Su DG, Hurwitz M, Braun DA, Kluger HM, Schoenfeld DA. Cancer Immunol Immunother. 2024 Aug 6; 2024 Aug 6. PMID: 39105820.
• GP100 expression is variable in intensity in melanoma.Mann JE, Hasson N, Su DG, Adeniran AJ, Smalley KSM, Djureinovic D, Jilaveanu LB, Schoenfeld DA, Kluger HM. Cancer Immunol Immunother. 2024 Aug 6; 2024 Aug 6. PMID: 39105816.
• A Th17 cell-intrinsic glutathione/mitochondrial-IL-22 axis protects against intestinal inflammation.Bonetti L, Horkova V, Grusdat M, Longworth J, Guerra L, Kurniawan H, Franchina DG, Soriano-Baguet L, Binsfeld C, Verschueren C, Spath S, Ewen A, Koncina E, Gérardy JJ, Kobayashi T, Dostert C, Farinelle S, Härm J, Fan YT, Chen Y, Harris IS, Lang PA, Vasiliou V, Waisman A, Letellier E, Becher B, Mittelbronn M, Brenner D. Cell Metab. 2024 Aug 6; 2024 Jul 9. PMID: 38986617.
• Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).Kozono D, Hua X, Wu MC, Tolba KA, Waqar SN, Dragnev KH, Cheng H, Hirsch FR, Mack PC, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman MW. J Thorac Oncol. 2024 Aug 5; 2024 Aug 5. PMID: 39111731.
• Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation.Gupta A, Barone C, Quijano E, Piotrowski-Daspit AS, Perera JD, Riccardi A, Jamali H, Turchick A, Zao W, Saltzman WM, Glazer PM, Egan ME. J Cyst Fibros. 2024 Aug 5; 2024 Aug 5. PMID: 39107154.
• Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting.Leapman MS, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot JA, Davicioni E, Martin DT, An Y, Seibert TM, Lin DW, Spratt DE, Cooperberg MR, Sprenkle PC, Ross AE. Eur Urol Oncol. 2024 Aug 3; 2024 Aug 3. PMID: 39098389.
• Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape.Weller M, Remon J, Rieken S, Vollmuth P, Ahn MJ, Minniti G, Le Rhun E, Westphal M, Brastianos PK, Soo RA, Kirkpatrick JP, Goldberg SB, Öhrling K, Hegi-Johnson F, Hendriks LEL. Cancer Treat Rev. 2024 Aug 2; 2024 Aug 2. PMID: 39151281.
• Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.Schoenfeld AJ, Lee SM, Doger de Spéville B, Gettinger SN, Häfliger S, Sukari A, Papa S, Rodríguez-Moreno JF, Graf Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller EL, Gontcharova V, He K. Cancer Discov. 2024 Aug 2. PMID: 38563600.
• CRISPR-based dissection of microRNA-23a ~ 27a ~ 24-2 cluster functionality in hepatocellular carcinoma.Cui M, Liu Z, Wang S, Bae S, Guo H, Zhou J, Liu R, Wang L. Oncogene. 2024 Aug; 2024 Aug 7. PMID: 39112518.
• Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer.Greenman M, Bellone S, Demirkiran C, Max Philipp Hartwich T, Santin AD. Gynecol Oncol Rep. 2024 Aug; 2024 Jul 13. PMID: 39108617.
• Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, Alistar AT, Oberstein PE, Golan T, Metges JP, Lacy J, Fountzilas C, Lopez CD, Ducreux M, Hammel P, Salem M, Bajor D, Benson AB, Luther S, Pardee T, Van Cutsem E. J Clin Oncol. 2024 Aug 1; 2024 Aug 1. PMID: 39088774.
• Burnout and career satisfaction in young neuro-oncology investigators: Results of the Society for Neuro-Oncology Young Investigator Survey.Youssef G, Acquaye-Mallory A, Vera E, Chheda MG, Dunn GP, Moliterno J, O'Brien BJ, Venere M, Yust-Katz S, Lee EQ, Armstrong TS. Neurooncol Pract. 2024 Aug; 2024 Mar 13. PMID: 39006527.
• Pancreatic Cancer Surveillance and Survival of High-Risk Individuals.Blackford AL, Canto MI, Dbouk M, Hruban RH, Katona BW, Chak A, Brand RE, Syngal S, Farrell J, Kastrinos F, Stoffel EM, Rustgi A, Klein AP, Kamel I, Fishman EK, He J, Burkhart R, Shin EJ, Lennon AM, Goggins M. JAMA Oncol. 2024 Aug 1. PMID: 38959011.
• Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Nat Med. 2024 Aug. PMID: 38914862.
• Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.Cecchini M, Salem RR, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend JP, Cai G, Chowdhury S, Yugawa D, Tseng R, Mejia Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan SA, Cha C, Billingsley KG, Kunstman JW, Johung KL, Wiess C, Muzumdar MD, Spickard E, Aushev VN, Laliotis G, Jurdi A, Liu MC, Escobar-Hoyos L, Lacy J. JAMA Oncol. 2024 Aug 1. PMID: 38900452.
• Latrophilin-2 mediates fluid shear stress mechanotransduction at endothelial junctions.Tanaka K, Chen M, Prendergast A, Zhuang Z, Nasiri A, Joshi D, Hintzen J, Chung M, Kumar A, Mani A, Koleske A, Crawford J, Nicoli S, Schwartz MA. EMBO J. 2024 Aug; 2024 Jun 17. PMID: 38886581.
• Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Nat Med. 2024 Aug; 2024 Jun 1. PMID: 38824244.
• Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Am J Hematol. 2024 Aug; 2024 May 15. PMID: 38751104.
• Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich TMP, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter J, Santin AD. Gynecol Oncol. 2024 Aug; 2024 May 3. PMID: 38703673.
• Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights.Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. JCO Oncol Pract. 2024 Aug; 2024 Apr 25. PMID: 38662970.
• Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan AM, Balmaceda NB, Yacoub A, Ai J, Knight TG, Ragon BK, Shah NA, Sanikommu SR, Symanowski J, Mesa R, Grunwald MR. Ann Hematol. 2024 Aug; 2024 Apr 25. PMID: 38662203.
• Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.Bewersdorf JP, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel J, Mendez L, Stahl M, Stein EM, Huntington SF, Goshua G, Zeidan AM. Leuk Lymphoma. 2024 Aug; 2024 Apr 22. PMID: 38648559.
• Identifying Opportunities to Deliver High-Quality Cancer Care Across a Health System: A Clinical Responsibility.Shah HP, Cohen O, Bourdillon AT, Burtness BA, Boffa DJ, Young M, Judson BL, Mehra S. Otolaryngol Head Neck Surg. 2024 Aug; 2024 Apr 12. PMID: 38606669.
• Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics.Gross M, Huber S, Arora S, Ze'evi T, Haider SP, Kucukkaya AS, Iseke S, Kuhn TN, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Aug; 2024 Jan 13. PMID: 38217704.
• Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms.Zeidan AM, Perepezko K, Salimi T, Washington T, Epstein RS. Ther Adv Hematol. 2024; 2024 Jul 30. PMID: 39091323.
• Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.Lee DY, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka JJ. Pigment Cell Melanoma Res. 2024 Jul 28; 2024 Jul 28. PMID: 39073002.